Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies 13/09/2018 by Intellectual Property Watch 6 Comments Marcela Fogaça Vieira and Pedro Villardi write: The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment was set for 6 September. The cancellation occurred on the eve of the judgment, something very rare in the practice of the Court. The lack of decision on the case only benefits the transnational companies awarded with hundreds of undue monopolies. Just a few days before, the President of the STF – Judge Carmem Lucia – had a meeting with Interfarma, the association of multinational pharmaceutical companies in Brazil.
UN Human Rights Council Begins; Freedom Of Expression Issues Highlighted By Article 19 Group 10/09/2018 by Intellectual Property Watch Leave a Comment Today, the UN Human Rights Council begins its 39th Session (HRC 39) in Geneva – over the next three weeks the UN’s top human rights body will come together to discuss and act on some of the world’s most pressing human rights violations and abuses, writes civil society group Article 19. There is a lot on the HRC’s agenda for September, with a number of issues important to the right to freedom of expression to be considered, and it is essential that the Council acts on improving protections. In addition to important reports from OHCHR and from special procedures up for discussion, several thematic and country-specific resolutions will also be negotiated, to be considered for adoption on 20 and 21 September.
New Dutch Foundation To Address High Medicines Pricing Announces Plan To File Complaint With Competition Authority 27/08/2018 by Intellectual Property Watch 1 Comment The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will request the Netherlands Authority for Consumers and Markets to look into the price hike for the medicine chenodeoxycholic acid (CDCA) by the company Leadiant Biosciences Ltd (formerly Sigma-Tau). CDCA is used for the treatment of children and adults with cerebrotendinous xanthomatosis (CTX), a rare genetic metabolic disease that affects around 60 people in the Netherlands.
Can A Surge In Activism Defeat American Big Pharma? 22/08/2018 by Guest contributor for Intellectual Property Watch Leave a Comment By Vinayak Bhardwaj – Not a day passes in America without news of a drug company raising prices on prescription drugs. Americans pay two to six times more for prescription drugs than those living in other developed countries, who earn the same income.
Report – Patent Abuse A Leading Cause Of High Drug Prices In US 03/08/2018 by Intellectual Property Watch 1 Comment Pharmaceutical companies have created an “untenable” situation by engaging in exploitative patenting practices to extend monopolies, increasing drug prices and delaying competition from more affordable generics, according to a new NGO report analysing drug prices.
Stakeholders Submit Views On South Africa Copyright Amendment 27/07/2018 by Linda Daniels for Intellectual Property Watch 1 Comment The call for public comments on the Copyright Amendment Bill by South Africa’s Parliamentary Portfolio Committee on Trade and Industry attracted a wide range of interest and contributions from local and international IP stakeholders.
Conceptualizing Minimum Core Beyond Affordable Goods And Services – Trade For Human Rights As A Minimum Core Obligation 26/07/2018 by Intellectual Property Watch Leave a Comment Prof. Sakiko Fukuda-Parr writes: The conception of the Minimum Core Doctrine around low cost goods and services is unnecessarily restrictive. It is also out of line with concerns to meet pressing and priority health needs of the population. It departs from the original concept of obligations of immediate effect. It limits the consideration of the wide range of measures that national governments should take to expand the enjoyment of the right to health such as by reversing damaging policies or setting new ones. A salient example is policy choices governments might make in the area of intellectual protection provisions in free trade and investment agreements.
NGOs: Countries Pressured To Drop Reference To Affordable Medicines In UN TB Negotiations 20/07/2018 by William New, Intellectual Property Watch 2 Comments United Nations members in the final days of negotiating the text of the declaration for a late September high-level meeting on tuberculosis have come under pressure from the United States to omit language referring to the importance of making affordable medicines available to patients in need, according to an urgent bulletin today from a health advocacy group.
Oppositions Filed Against Gilead Hepatitis C Patent Applications In India 20/07/2018 by Gaensly Joseph for Intellectual Property Watch 2 Comments Oppositions have been filed in India against two patent applications from US pharmaceutical company Gilead for important hepatitis C medicines, according to non-governmental sources. The opposition filings assert that these applications are “evergreening” patents and therefore violate Indian patent law.
Study Reconsiders “Public Domain” In The Protection Of Traditional Knowledge 11/07/2018 by Damilola Adepeju for Intellectual Property Watch 1 Comment A recent study has revisited the meaning of “public domain” in line with its usage in discussions on protection of traditional knowledge (TK). The study highlights that it provides a non-Eurocentric conception of “public domain” in order to recognise the customary laws and practices of indigenous and local communities (ILCs).